Physician profile
Lee Monlezun
NPI 1902973092
$953.99
in general payments reported to CMS, 2019-2025
12 companies · $15.68 in 2025
The $15.68 reported for 2025 was less than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $106 · 2021: $208 · 2022: $63.95 · 2023: $49.80 · 2024: $237 · 2025: $15.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $208 · Education: $93.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $208.11 |
| Education | $93.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $201.98 | 2019-2022 | |
| Astellas Pharma US INC | $167.94 | 2023-2024 | Veozah |
| Intuitive Surgical, INC. | $117.24 | 2021 | |
| Millicent US INC | $76.68 | 2019-2025 | Intrarosa, Femring |
| Hologic Sales and Service, LLC | $73.07 | 2019-2023 | Acessa Provu System, Myosure Tissue Removal Device |
| Channel Medsystems, INC. | $68.00 | 2024 | |
| Avion Pharmaceuticals | $67.59 | 2019-2023 | Balcoltra |
| Novo Nordisk INC | $57.64 | 2019-2022 | |
| Vivus LLC | $51.58 | 2019 | |
| Amag Pharmaceuticals, INC. | $40.19 | 2019 | |
| Abbvie INC. | $17.63 | 2019 | |
| Currax Pharmaceuticals LLC | $14.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Monlezun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.